Imipraminoxide

Imipraminoxide

Skeletal formula of imipraminoxide
Ball-and-stick model of the Imipraminoxide molecule
Systematic (IUPAC) name
3-(5,6-dihydrobenzo[b][f]benzazepin- 11-yl)- N,N-dimethyl- propan- 1-amine N-oxide
Clinical data
Legal status	℞ (Prescription only)
Routes of administration	oral
Identifiers
CAS Number	6829-98-7
ATC code	N06AA03 (WHO)
PubChem	CID: 65589
ChemSpider	59031
UNII	8MKS280XJW Y
KEGG	D07334
ChEMBL	CHEMBL1614644
Chemical data
Formula	C19H24N2O
Molecular mass	296.41 g/mol

Imipraminoxide (Imiprex, Elepsin), or imipramine N-oxide, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.

Imipraminoxide is both an analogue and a metabolite of imipramine, and has similar effects. However, in clinical trials, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked side effects, including diminished orthostatic hypotension and anticholinergic effects like dry mouth, sweating, dizziness, and fatigue.

Imipraminoxide's pharmacology has not been well elucidated, but based on its very close relationship with imipramine, it likely acts as a serotonin and norepinephrine reuptake inhibitor and serotonin, adrenenaline, histamine, and muscarinic acetylcholine receptor antagonist, though with weaker antiadrenergic and anticholinergic actions.

See also

• Amitriptylinoxide